Evidence map›Paper›PMID 37310791›Full record

ArticleJCI insight2023

Calcineurin regulates aldosterone production via dephosphorylation of NFATC4.

Mesut Berber, Sining Leng, Agnieszka Wengi, Denise V Winter, Alex Odermatt, Felix Beuschlein, Johannes Loffing, David T Breault, David Penton

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Calcineurin inhibitor effects on kidney electrolyte handling and blood pressure: tacrolimus versus voclosporin.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Article
  6. Role of calcineurin in regulating renal potassium (KActa physiologica (Oxford, England) · 2024
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Mesut BerberInstitute of Anatomy, University of Zurich, Switzerland.
Sining LengDepartment of Pediatrics, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA.
Agnieszka WengiInstitute of Anatomy, University of Zurich, Switzerland.
Denise V WinterSwiss Centre for Applied Human Toxicology and Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Alex OdermattSwiss Centre for Applied Human Toxicology and Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Felix BeuschleinSwiss National Centre for Competence in Research "Kidney Control of Homeostasis" (NCCR Kidney.CH), Zurich, Switzerland.
Johannes LoffingInstitute of Anatomy, University of Zurich, Switzerland.
David T BreaultDepartment of Pediatrics, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA.
David PentonInstitute of Anatomy, University of Zurich, Switzerland.
National Kidney Foundation · USBoston University · USUniversity of Basel · CHUniversity of Zurich · CH

Funding

Rosettes in Adrenal Development, Maintenance and DiseaseR01DK123694 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI David T Breault · 2019 to 2026
$5.6M
NIDDK NIH HHS R01 DK123694
6 · The paper itself

Abstract

The mineralocorticoid aldosterone, secreted by the adrenal zona glomerulosa (ZG), is critical for life, maintaining ion homeostasis and blood pressure. Therapeutic inhibition of protein phosphatase 3 (calcineurin, Cn) results in inappropriately low plasma aldosterone levels despite concomitant hyperkalemia and hyperreninemia. We tested the hypothesis that Cn participates in the signal transduction pathway regulating aldosterone synthesis. Inhibition of Cn with tacrolimus abolished the potassium-stimulated (K+-stimulated) expression of aldosterone synthase, encoded by CYP11B2, in the NCI-H295R human adrenocortical cell line as well as ex vivo in mouse and human adrenal tissue. ZG-specific deletion of the regulatory Cn subunit CnB1 diminished Cyp11b2 expression in vivo and disrupted K+-mediated aldosterone synthesis. Phosphoproteomics analysis identified nuclear factor of activated T cells, cytoplasmic 4 (NFATC4), as a target for Cn-mediated dephosphorylation. Deletion of NFATC4 impaired K+-dependent stimulation of CYP11B2 expression and aldosterone production while expression of a constitutively active form of NFATC4 increased expression of CYP11B2 in NCI-H295R cells. Chromatin immunoprecipitation revealed NFATC4 directly regulated CYP11B2 expression. Thus, Cn controls aldosterone production via the Cn/NFATC4 pathway. Inhibition of Cn/NFATC4 signaling may explain low plasma aldosterone levels and hyperkalemia in patients treated with tacrolimus, and the Cn/NFATC4 pathway may provide novel molecular targets to treat primary aldosteronism.

Indexed as

AldosteroneCalcineurinHyperkalemiaNFATC Transcription FactorsAnimalsCytochrome P-450 CYP11B2HumansMiceTacrolimusAldosteroneCalcineurinCytochrome P-450 CYP11B2NFATC4 protein, humanNFATC Transcription FactorsTacrolimusEndocrinologyMetabolismPhosphoprotein phosphatasesSignal transduction

Identifiers

PMID37310791
PMCPMC10443813
OpenAlexW4380480103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.